Effects of Sequential Vs Single Pneumococcal Vaccination on Cardiovascular Diseases Among Older Adults: a Population-based Cohort Study

Overview

Journal Int J Epidemiol

Specialty Public Health

Date 2024 Feb 9

PMID 38332579

Authors

Xinning Tong

Le Gao

Ian C K Wong

Vivien K Y Chan

Angel Y S Wong

Judith C W Mak

Jacqueline K Y Yuen

Mark Jit

Ivan F N Hung

Kai Hang Yiu

Xue Li

Affiliations

Soon will be listed here.

Abstract

Background: Recommendations around the use of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) seldom focus on potential benefits of vaccine on comorbidities. We aimed to investigate whether sequential vaccination with PCV13 and PPSV23 among older adults would provide protection against cardiovascular diseases (CVD) compared with using a single pneumococcal vaccine.

Methods: We conducted a Hong Kong-wide retrospective cohort study between 2012 and 2020. Adults aged ≥65 years were identified as receiving either a single or sequential dual vaccination and followed up until the earliest CVD occurrence, death or study end. To minimize confounding, we matched each person receiving a single vaccination to a person receiving sequential vaccination according to their propensity scores. We estimated the hazard ratio (HR) of CVD risk using Cox regression and applied structural equation modelling to test whether the effect of sequential dual vaccination on CVD was mediated via the reduction in pneumonia.

Results: After matching, 69 390 people remained in each group and the median (interquartile range) follow-up time was 1.89 (1.55) years. Compared with those receiving a single vaccine, those receiving sequential dual vaccination had a lower risk of CVD [HR (95% CI): 0.75 (0.71, 0.80), P < 0.001]. Post-hoc mediation analysis showed strong evidence that the decreased CVD risk was mediated by the reduction in all-cause pneumonia.

Conclusions: Sequential dual pneumococcal vaccination was associated with lower risk of CVD compared with single-dose PCV13 or PPSV23 in older adults. Such additional CVD benefits should be considered when making decisions about pneumococcal vaccination.

References

Marra F, Zhang A, Gillman E, Bessai K, Parhar K, Vadlamudi N . The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis. 2020; 99:204-213. DOI: 10.1016/j.ijid.2020.07.038. View

Restrepo M, Reyes L . Pneumonia as a cardiovascular disease. Respirology. 2018; 23(3):250-259. DOI: 10.1111/resp.13233. View

Li X, Tong X, Yeung W, Kuan P, Yum S, Chui C . Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2021; 81(4):564-568. PMC: 8550868. DOI: 10.1136/annrheumdis-2021-221571. View

Yazdanyar A, Newman A . The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009; 25(4):563-77, vii. PMC: 2797320. DOI: 10.1016/j.cger.2009.07.007. View

Douros A, Lix L, Fralick M, DellAniello S, Shah B, Ronksley P . Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Ann Intern Med. 2020; 173(6):417-425. DOI: 10.7326/M20-0289. View

Hu Y, Han Y, Yu C, Guo Y, Pei P, Yang L . The hospitalization burden of all-cause pneumonia in China: A population-based study, 2009-2017. Lancet Reg Health West Pac. 2022; 22:100443. PMC: 8991381. DOI: 10.1016/j.lanwpc.2022.100443. View

Wiese A, Griffin M, Grijalva C . Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019; 18(4):327-341. PMC: 6443450. DOI: 10.1080/14760584.2019.1582337. View

Antunes M, Duarte G, Brito D, Borges M, Costa J, Ferreira J . Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2020; 7(1):97-106. DOI: 10.1093/ehjqcco/qcaa030. View

Austin P . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010; 10(2):150-61. PMC: 3120982. DOI: 10.1002/pst.433. View

10.

Greenberg R, Gurtman A, Frenck R, Strout C, Jansen K, Trammel J . Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine. 2014; 32(20):2364-74. DOI: 10.1016/j.vaccine.2014.02.002. View

11.

Girerd N, Chapet N, Roubille C, Roncalli J, Salvat M, Mouquet F . Vaccination for Respiratory Infections in Patients with Heart Failure. J Clin Med. 2021; 10(19). PMC: 8509310. DOI: 10.3390/jcm10194311. View

12.

Bogaert D, de Groot R, Hermans P . Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4(3):144-54. DOI: 10.1016/S1473-3099(04)00938-7. View

13.

Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K . Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015; (5):CD005050. PMC: 8511741. DOI: 10.1002/14651858.CD005050.pub3. View

14.

Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T . Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68(46):1069-1075. PMC: 6871896. DOI: 10.15585/mmwr.mm6846a5. View

15.

Moore M, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett N . Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15(3):301-9. PMC: 4876855. DOI: 10.1016/S1473-3099(14)71081-3. View

16.

Corrales-Medina V, Musher D, Shachkina S, Chirinos J . Acute pneumonia and the cardiovascular system. Lancet. 2013; 381(9865):496-505. DOI: 10.1016/S0140-6736(12)61266-5. View

17.

Hung I, Leung A, Chu D, Leung D, Cheung T, Chan C . Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010; 51(9):1007-16. DOI: 10.1086/656587. View

18.

Nguyen T, Collins G, Spence J, Daures J, Devereaux P, Landais P . Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017; 17(1):78. PMC: 5408373. DOI: 10.1186/s12874-017-0338-0. View

19.

Li X, Tong X, Wong I, Peng K, Chui C, Lai F . Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut. 2022; 71(12):2608-2611. DOI: 10.1136/gutjnl-2021-326860. View

20.

van Deursen A, van Houten M, Webber C, Patton M, Scott D, Patterson S . Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin Infect Dis. 2017; 65(5):787-795. DOI: 10.1093/cid/cix419. View